Gilead Sciences Inc vs Abbvie Inc.
GILD vs ABBV — side-by-side comparison from reported financials. GILD leads 6, ABBV leads 4 of 10 comparable metrics.
Gilead Sciences Inc
GILD · Healthcare
$151.20+2.79%Mixed
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | GILD | ABBV |
|---|---|---|
| Price | $151.20 | $276.43 |
| Market cap | $187B | $488B |
| Revenue (TTM) | $30.5B | $64.4B |
| Revenue growth | +2.6% | +1.8% |
| Net margin | -10.6% | 9.8% |
| Free cash flow | $12.9B | $18.2B |
| Net cash (debt) | ($24.9B) | ($56.2B) |
| 1-year price return | +29.5% | +19.8% |
| P/E | 22.0 | 77.4 |
| P/E vs own history (cheap-side %) | 78% | 23% |
| Dividend yield | 3.24% | 2.45% |
| Return on equity | -16% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 9 of 11 | 9 of 11 |
| Employees | 17,000 | 57,000 |
Full résumé-style profiles: GILD CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.